ALMS Projected Dividend Yield
Alumis Inc ( NASDAQ : ALMS )Alumis is a clinical stage biopharmaceutical company focused on Tyrosine Kinase 2 (TYK2) inhibitors, ESK-001, a second-generation inhibitor maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. 21 YEAR PERFORMANCE RESULTS |
ALMS Dividend History Detail ALMS Dividend News ALMS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |